Literature DB >> 28416539

Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.

M C Arendrup1,2,3, Anupam Prakash4, Joseph Meletiadis5,6, Cheshta Sharma4, Anuradha Chowdhary4.   

Abstract

Candida auris is an emerging multidrug-resistant yeast. So far, all but two susceptibility testing studies have examined ≤50 isolates, mostly with the CLSI method. We investigated CLSI and EUCAST MICs for 123 C. auris isolates and eight antifungals and evaluated various methods for epidemiological cutoff (ECOFF) determinations. MICs (in milligrams per liter) were determined using CLSI method M27-A3, and the EUCAST E.Def 7.3. ANOVA analysis of variance with Bonferroni's multiple-comparison test and Pearson analysis were used on log2 MICs (significance at P values of <0.05). The percent agreement (within ±0 to ±2 2-fold dilutions) between the methods was calculated. ECOFFs were determined visually, statistically (using the ECOFF Finder program and MicDat1.23 software with 95% to 99% endpoints), and via the derivatization method (dECOFFs). The CLSI and EUCAST MIC distributions were wide, with several peaks for all compounds except amphotericin B, suggesting possible acquired resistance. Modal MIC, geometric MIC, MIC50, and MIC90 values were ≤1 2-fold dilutions apart, and no significant differences were found. The quantitative agreement was best for amphotericin B (80%/97% within ±1/±2 dilutions) and lowest for isavuconazole and anidulafungin (58%/76% to 75% within ±1/±2 dilutions). We found that 90.2%/100% of the isolates were amphotericin B susceptible based on CLSI/EUCAST methods, respectively (i.e., with MICs of ≤1 mg/liter), and 100%/97.6% were fluconazole nonsusceptible by CLSI/EUCAST (MICs > 2). The ECOFFs (in milligrams per liter) were similar across the three different methods for itraconazole (ranges for CLSI/EUCAST, 0.25 to 0.5/0.5 to 1), posaconazole (0.125/0.125 to 0.25), amphotericin B (0.25 to 0.5/1 to 2), micafungin (0.25 to 0.5), and anidulafungin (0.25 to 0.5/0.25 to 1). In contrast, the estimated ECOFFs were dependent on the method applied for voriconazole (1 to 32) and isavuconazole (0.125 to 4). CLSI and EUCAST MICs were remarkably similar and confirmed uniform fluconazole resistance and variable acquired resistance to the other agents.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida auris; ECOFF; MIC; amphotericin B; antifungal susceptibility testing; azoles; echinocandins; in vitro

Mesh:

Substances:

Year:  2017        PMID: 28416539      PMCID: PMC5444165          DOI: 10.1128/AAC.00485-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

Review 2.  Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.

Authors:  Florent Morio; Cedric Loge; Bernard Besse; Christophe Hennequin; Patrice Le Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

3.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods.

Authors:  Jong Hee Shin; Mi-Na Kim; Sook Jin Jang; Min Young Ju; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

5.  Candida auris candidaemia in Indian ICUs: analysis of risk factors.

Authors:  Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Raees A Paul; Prashant Sood; Harsimran Kaur; Malini R Capoor; Anupma J Kindo; Rungmei S K Marak; Anita Arora; Raman Sardana; Shukla Das; Deepinder Chhina; Atul Patel; Immaculata Xess; Bansidhar Tarai; Pankaj Singh; Anup Ghosh
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

6.  Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.

Authors:  Rasmus Hare Jensen; Karen Marie Thyssen Astvad; Luis Vale Silva; Dominique Sanglard; Rene Jørgensen; Kristian Fog Nielsen; Estella Glintborg Mathiasen; Ghazalel Doroudian; David Scott Perlin; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2015-05-27       Impact factor: 5.790

7.  Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

8.  Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism.

Authors:  A Prakash; C Sharma; A Singh; P Kumar Singh; A Kumar; F Hagen; N P Govender; A L Colombo; J F Meis; A Chowdhary
Journal:  Clin Microbiol Infect       Date:  2015-11-05       Impact factor: 8.067

9.  Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital.

Authors:  Kazuo Satoh; Koichi Makimura; Yayoi Hasumi; Yayoi Nishiyama; Katsuhisa Uchida; Hideyo Yamaguchi
Journal:  Microbiol Immunol       Date:  2009-01       Impact factor: 1.955

10.  Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.

Authors:  Ronen Ben-Ami; Judith Berman; Ana Novikov; Edna Bash; Yael Shachor-Meyouhas; Shiri Zakin; Yasmin Maor; Jalal Tarabia; Vered Schechner; Amos Adler; Talya Finn
Journal:  Emerg Infect Dis       Date:  2017-02       Impact factor: 6.883

View more
  76 in total

1.  Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris.

Authors:  Xin Hou; Annie Lee; Cristina Jiménez-Ortigosa; Milena Kordalewska; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  In vitro activity of isavuconazole against clinically isolated yeasts from Chile.

Authors:  Eduardo Álvarez Duarte; Valentina Salas
Journal:  Braz J Microbiol       Date:  2020-07-07       Impact factor: 2.476

3.  Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs.

Authors:  Maiken Cavling Arendrup; Anuradha Chowdhary; Karin Meinike Jørgensen; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 4.  Candida auris: a Review of the Literature.

Authors:  Anna Jeffery-Smith; Surabhi K Taori; Silke Schelenz; Katie Jeffery; Elizabeth M Johnson; Andrew Borman; Rohini Manuel; Colin S Brown
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

5.  Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome.

Authors:  Ziauddin Khan; Suhail Ahmad; Khalifa Benwan; Prashant Purohit; Inaam Al-Obaid; Ritu Bafna; Maha Emara; Eiman Mokaddas; Aneesa Ahmed Abdullah; Khaled Al-Obaid; Leena Joseph
Journal:  Infection       Date:  2018-06-14       Impact factor: 3.553

6.  In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen; Rasmus Krøger Hare; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.

Authors:  Andrew M Borman; Julian Muller; Jo Walsh-Quantick; Adrien Szekely; Zoe Patterson; Michael D Palmer; Mark Fraser; Elizabeth M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

8.  Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris.

Authors:  Shawn R Lockhart; Brendan R Jackson; Snigdha Vallabhaneni; Luis Ostrosky-Zeichner; Peter G Pappas; Tom Chiller
Journal:  J Clin Microbiol       Date:  2017-09-13       Impact factor: 5.948

9.  In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.

Authors:  YanChun Zhu; Shannon Kilburn; Mili Kapoor; Sudha Chaturvedi; Karen Joy Shaw; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 10.  Candida auris: an Emerging Fungal Pathogen.

Authors:  Emily S Spivak; Kimberly E Hanson
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.